Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Impact of the Vega Healthcare Provider Report on Provider Satisfaction and Decision-Making Confidence in Simulated Patient Portal Visits for Migraine
Headache
Headache Posters (7:00 AM-5:00 PM)
143

Patient portals of many electronic health records (EHRs) allow patients to securely send time-sensitive questions to providers, who frequently require further clarifying questions following EHR review to make informed decisions. Vega allows patients to log migraine-related data and medication usage in real-time and compile these into an HPR to facilitate patient-provider communication and decision-making confidence in care.

To evaluate satisfaction with the healthcare provider report (HPR) from a migraine smartphone app (Vega), and its impact on provider confidence in decision-making in simulated patient portal communications.

Twelve Mass General Brigham providers (neurologists and primary care) received 10 standardized simulated cases mimicking typical patient portal communications after an initial visit, accompanied by EHR data (medical history, physical, laboratory/imaging data, and initial assessment and plan). For each provider, cases were randomized 1:1 so that half included a Vega HPR. Providers sent their medical decisions to a proctor, who provided additional information if requested. After each case, providers scored their confidence in their decision and satisfaction with the Vega HPR on a 5-point Likert scale (5=most confident /satisfied). Mean confidence scores of the Vega HPR and Non-HPR groups were compared using a linear mixed effect model, and mean satisfaction score for the Vega HPRs was calculated.

The mean confidence scores for Non-HPR and Vega HPR cases were 3.88 (95% CI, 3.53-4.23) and 4.40 (95% CI, 4.05-4.75), respectively. The difference between means was 0.517 (95% CI, 0.21-0.83, p=0.0013), demonstrating that access to a Vega HPR improved provider confidence in their medical decision. Mean satisfaction with the Vega HPR was 4.633 (SD 0.663, IQR 1, median 5) out of 5, indicating high satisfaction with the reports.

Providers responding to simulated patient portal encounters with the additional Vega HPR data were more confident in their decision-making and reported a high level of satisfaction with the HPR.

Authors/Disclosures
Paul B. Rizzoli, MD, FAAN (BW/F Neurology)
PRESENTER
Dr. Rizzoli has received personal compensation in the range of $0-$499 for serving as a Consultant for CVS. Dr. Rizzoli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Rizzoli has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. Dr. Rizzoli has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Harvard Health Publishing. The institution of Dr. Rizzoli has received research support from Abbvie. Dr. Rizzoli has received publishing royalties from a publication relating to health care.
Melissa Darsey, PA (Brigham and Women's Hospital) Melissa Darsey has a non-compensated relationship as a Clinical Research Assistant with Allergan that is relevant to AAN interests or activities.
Katherine Selzler Katherine Selzler has received personal compensation for serving as an employee of Eli Lilly and Company. Katherine Selzler has received stock or an ownership interest from Eli Lilly and Company.
Ju Ji Ju Ji has nothing to disclose.
Bill Prucka (Eli Lilly and Company) Bill Prucka has received personal compensation for serving as an employee of Eli Lilly and Company. Bill Prucka has stock in Eli Lilly and Company.
Bert B. Vargas, MD, FAAN (Eli Lilly and Company) Dr. Vargas has received personal compensation for serving as an employee of Lilly USA. Dr. Vargas has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for ElevateMed. Dr. Vargas has stock in Eli Lilly. An immediate family member of Dr. Vargas has stock in Pfizer. Dr. Vargas has received personal compensation in the range of $500-$4,999 for serving as a Unaffiliated Neurotrauma Consultant with National Football League. Dr. Vargas has received personal compensation in the range of $10,000-$49,999 for serving as a Neurotrauma Consultant with National Association for Stock Car Auto Racing.